Search ARM

LyGenesis is a clinical-stage biotechnology company whose cell therapies use patients’ lymph nodes as bioreactors to regrow functioning ectopic organs. LyGenesis’s lead allogeneic cell therapy program is currently in a Phase 2a clinical trial for patients with end stage liver disease. LyGenesis’s drug development pipeline includes cell therapies that can produce an ectopic thymus (for aging and multiple other potential indications), pancreas (for Type 1 diabetes), and kidney (for end stage renal disease). Its drug development pipeline also includes orphan pediatric indications involving inborn errors of metabolism. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.

Contact LyGenesis
Visit Website